Publications by authors named "A J Sijts"
Article Synopsis
- Chlamydia trachomatis is the most common bacterial STI globally, making vaccine development challenging due to its complex lifecycle and poor antigen delivery methods.
- Recent research focused on using bacterial protein bodies (PBs) to deliver vaccine antigens, specifically testing the efficacy of PBs containing specific Chlamydia antigens in mice.
- Results showed that the PB-CTH522-SP vaccine not only induced strong immune responses but also significantly reduced bacterial counts in mice after exposure to Chlamydia, suggesting PBs could be a viable platform for effective vaccine development.
is an obligate intracellular pathogen responsible for the most prevalent bacterial sexually transmitted disease globally. The high prevalence of chlamydial infections underscores the urgent need for licensed and effective vaccines to prevent transmission in populations. Bacterial outer membrane vesicles (OMVs) have emerged as promising mucosal vaccine carriers due to their inherent adjuvant properties and the ability to display heterologous antigens.
View Article and Find Full Text PDFMacrophages can reversibly polarize into multiple functional subsets depending on their micro-environment. Identification and understanding the functionality of these subsets is relevant for the study of immune‑related diseases. However, knowledge about canine macrophage polarization is still in its infancy.
View Article and Find Full Text PDFUnlabelled: In the last decades, antibody-based tumor therapy has fundamentally improved the efficacy of treatment for patients with cancer. Currently, almost all tumor antigen-targeting antibodies approved for clinical application are of IgG1 Fc isotype. Similarly, the mouse homolog mIgG2a is the most commonly used in tumor mouse models.
View Article and Find Full Text PDFArticle Synopsis
- T cell engager (TCE) antibodies are innovative cancer treatments that connect T-cells to tumor cells by binding to both T-cell receptors (CD3E) and tumor markers (TAA).
- The study focuses on a bispecific antibody format (IgG-like Fab x sdAb-Fc) that targets mEGFR on tumors and mCD3E on T-cells, analyzing the effect of hinge design in the sdAb.
- The findings reveal that a shorter hinge (23 amino acids) enhances tumor cell elimination and T-cell activation compared to a longer hinge (39 amino acids), suggesting that small design modifications can significantly boost the effectiveness of these therapeutic antibodies.